Mission Statement, Vision, & Core Values of I-Mab (IMAB)

I-Mab, which is currently undergoing a strategic transformation and rebrand to NovaBridge Biosciences, is valued at a $0.53 Billion USD market capitalization as of November 2025 and holds a robust $168.8 million in cash to fund its lead pipeline asset, givastomig. This shift-from a U.S.-focused clinical-stage biotech to a global platform pursuing a dual NASDAQ and HKEX listing-defintely requires a clear, unwavering organizational compass to guide its new business model. Do the company's stated Mission of Bringing Transformational Medicines to Patients Through Innovation and its Core Values truly align with this aggressive, value-creation strategy, and how should you model the risk of an organization in flux?

I-Mab (IMAB) Overview

You are looking at I-Mab (IMAB), a company that has executed a sharp strategic pivot to focus its entire effort on a single, high-potential asset. This U.S.-based global biotech, founded in 2014, is exclusively dedicated to developing precision immuno-oncology agents, essentially next-generation cancer treatments. They recently divested their Greater China assets to become a streamlined, clinical-stage entity.

The company's core product and primary focus is givastomig, a bispecific antibody (a drug engineered to bind to two different targets) that hits Claudin 18.2 (CLDN18.2) and 4-1BB. This is a big bet on a single drug candidate, but it's a calculated one targeting a significant unmet need: first-line gastric cancers. As a clinical-stage company, I-Mab (IMAB) does not yet generate revenue from product sales, so its reported sales for the first half of the 2025 fiscal year were $0.000. That's the reality for a biotech focused on development, not commercialization yet.

• Focus: Precision immuno-oncology.
• Lead Asset: Givastomig for gastric cancer.
• 2025 Sales: $0.000 from product sales.

Here's the quick math: they are spending money to make money later, which means their value is in the pipeline data, not current sales. To be defintely accurate, you should know that the company transitioned its brand to NovaBridge Biosciences, effective October 30, 2025, reflecting this strategic transformation, but we'll refer to them as I-Mab (IMAB) for consistency with the historical entity.

Financial Performance and Pipeline Momentum in 2025

The latest financial reports, covering the first half of 2025, show a company shoring up its balance sheet to fund its critical clinical trials. While they don't have product revenue, the key financial metric for a company at this stage is their cash runway (how long their money lasts) and their spending efficiency. I-Mab (IMAB) reported a net loss of $(5.5) million for the second quarter of 2025, an improvement over the net loss from continuing operations of $(8.9) million in the comparable period of 2024.

The real story is the cash. Following a successful underwritten offering in August 2025 that raised net proceeds of approximately $61.2 million, I-Mab (IMAB)'s pro-forma cash and short-term investments stood at approximately $226.8 million as of June 30, 2025. This strong cash position is expected to fund all planned operations and capital expenditures through the fourth quarter of 2028. That's a long runway, giving them ample time to reach major data readouts.

The most important growth indicator isn't sales, but the clinical data for givastomig. The drug showed an impressive 83% objective response rate (ORR) in Phase 1b dose escalation for first-line gastric cancers when combined with immunochemotherapy. This is the main product's 'sales' equivalent right now-a strong clinical signal that drives market confidence and future valuation. Plus, Research and Development expenses were down to $3.3 million for Q2 2025, compared to $5.2 million in Q2 2024, showing a tight focus on core assets.

A Focused Leader in Immuno-Oncology

I-Mab (IMAB) is positioning itself as a leader not by market share today, but by the potential of its targeted, high-efficacy pipeline. They are a focused clinical-stage biotech, which is a key player in the global biotech landscape because of their proprietary drug discovery platforms and cross-border collaboration model.

The company is concentrating on immuno-oncology, one of the fastest-growing and most dynamic areas in modern medicine. Their success hinges on givastomig's ability to be a 'best-in-class' Claudin 18.2-directed therapy. The acquisition of Bridge Health in 2025, which strengthened the intellectual property portfolio for givastomig, further shows their commitment to owning the future of this asset.

A strong cash runway through Q4 2028 and compelling early clinical data are what make I-Mab (IMAB) a notable entity in the biopharma space. They are not a commercial leader yet, but a pipeline leader in the making. If you want to understand the individuals betting on this strategy, you should check out Exploring I-Mab (IMAB) Investor Profile: Who's Buying and Why?

I-Mab (IMAB) Mission Statement

You're looking at I-Mab (IMAB) and trying to map their long-term value, and honestly, you have to start with their mission. A company's mission statement isn't just marketing fluff; it's the operating thesis that guides capital allocation and R&D decisions. For I-Mab, that thesis is clear: Bringing Transformational Medicines to Patients Through Innovation. This is the core directive, and it's especially vital now as they execute a major strategic shift to become a global biotech platform. This mission is what connects their R&D spending to a patient outcome, and it's the lens through which we should view their recent 2025 financial and clinical data.

Here's the quick math: if the mission is transformational medicines, the output must be best-in-class assets with compelling clinical data. It's a high bar, but the firm's recent focus on its lead asset, givastomig, shows a defintely strategic alignment with this goal. To understand the full picture, you need to break down the three core components that underpin this mission.

For a deeper dive into their balance sheet, check out Breaking Down I-Mab (IMAB) Financial Health: Key Insights for Investors.

Component 1: Innovation in Precision Immuno-Oncology

The first pillar of the mission is the commitment to Innovation, which I-Mab translates directly into its focus on precision immuno-oncology agents. This means developing novel biologics-like bispecific antibodies-that target cancer with greater accuracy and efficacy than older treatments. They aren't chasing me-too drugs; they're aiming for first-in-class or best-in-class therapies.

A concrete example of this commitment is the progress of their lead candidate, givastomig. The positive Phase 1b dose escalation data presented at ESMO GI in July 2025 showed an impressive 83% Objective Response Rate (ORR) when givastomig was combined with immunochemotherapy for first-line gastric cancers. This kind of efficacy data is the ultimate proof point for a mission centered on 'transformational medicines.' The company also completed enrollment in the planned Phase 1b dose expansion cohorts ahead of schedule, demonstrating operational excellence behind the innovation.

• Focus on novel biologics like bispecific antibodies.
• Givastomig Phase 1b ORR hit 83% in gastric cancer.
• Clinical progress is accelerating.

Component 2: Accelerating Global Access and Reach

The second critical component is Bringing... to Patients, specifically on a global scale. This isn't just about developing a drug; it's about building a business model that can deliver it worldwide. In October 2025, I-Mab announced a strategic transformation to become a global biotech platform, explicitly committed to 'accelerating access to innovative medicines for patients worldwide.'

This strategic shift is a direct action tied to the mission. It involves a business model focused on global capabilities, bridging science and strategy to advance breakthrough assets. The intention to pursue a Hong Kong IPO, dual-listing on NASDAQ and HKEX, is a financial move designed to expand access to global capital and innovation. This capital structure change is designed to fund the global rollout of assets like givastomig, ensuring the innovation reaches the patients who need it most, particularly the over 250,000 people globally affected by gastric cancers.

Component 3: Strategic Value Creation and Financial Discipline

The third, and often overlooked, component is the financial discipline necessary to sustain the mission-the Innovation part requires cash. The 2025 financial results show a strong focus on strategic value creation through streamlined operations. In Q2 2025, I-Mab reported R&D expenses of just $3.3 million, a significant decrease from $5.2 million in the same quarter of 2024. This reduction reflects a strategic reprioritization and streamlined clinical pipeline activities, not a retreat from research.

The company has substantially strengthened its balance sheet to ensure the mission is financially viable. Following an underwritten offering in August 2025, the pro-forma cash balance stood at approximately $226.8 million as of June 30, 2025. This war chest is expected to provide an operational runway through the fourth quarter of 2028, funding the critical randomized Phase 2 trial of givastomig. That's a clear line from a strong balance sheet to the ability to deliver on the mission's promise.

I-Mab (IMAB) Vision Statement

You're looking at I-Mab (IMAB) at a pivotal moment, a company that has defintely shifted its entire operating model in 2025. The core vision has moved from a traditional biotech pipeline to a more agile, platform-based approach. The new strategic vision is to become a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide. This isn't just a name change-they intend to rebrand as NovaBridge Biosciences-it's a fundamental business model transformation designed to maximize asset value and extend their financial runway through the fourth quarter of 2028.

The old tagline, Transforming Potential into Reality, is now being executed through a new, globally-focused strategy. This means less internal, early-stage discovery and more clinical-stage asset acquisition and rapid proof-of-concept (POC) execution.

Accelerating Access to Innovative Medicines

The mission remains clear: Bringing Transformational Medicines to Patients Through Innovation. The near-term focus is on their lead immuno-oncology agent, givastomig (a bispecific antibody targeting CLDN18.2 and 4-1BB), which is the most concrete example of this mission in action. This program is why I-Mab is positioned as a precision oncology player.

The data here is compelling. In the Phase 1b combination study for first-line gastric cancers, givastomig demonstrated an impressive 83% Objective Response Rate (ORR). That's a powerful signal in a high-unmet-need area, and it's driving their plan to start a global randomized Phase 2 study in Q1 2026. They're also looking at patient subgroups, like those with low Claudin and low PD-L1 expression, who are currently not eligible for other key treatments. This targeted approach shows their commitment to patient access where options are scarce.

• Focus clinical efforts where patient need is highest.
• Drive givastomig into global Phase 2 trials quickly.
• Leverage translational expertise for rapid POC.

Global Biotech Platform and Capital Strategy

The new vision is fundamentally about global reach and financial flexibility. The strategic transformation, announced in October 2025, positions I-Mab as a global platform, moving beyond its previous U.S.-focused clinical-stage biotech model. This is a smart move to diversify capital access and accelerate growth.

The balance sheet is strong following the strategic shift and capital raise. After an underwritten offering in August 2025, the pro-forma cash balance stood at approximately $226.8 million as of June 30, 2025. This cash position is expected to fund operations through the fourth quarter of 2028. Here's the quick math: that cash runway buys them critical time to hit major clinical milestones for givastomig and the recently acquired VIS-101, which is a novel bifunctional biologic for serious eye disorders. Plus, the intention to pursue a Hong Kong IPO through a dual listing on NASDAQ and the HKEX is a direct move to expand access to global capital. For a deeper dive into the numbers, you can check out Breaking Down I-Mab (IMAB) Financial Health: Key Insights for Investors.

Driving Value Through Translational Clinical Development

The platform model is built on efficiency, which you can see in the 2025 financial statements. The company is actively streamlining operations, particularly after divesting its Greater China assets. This strategic focus led to a significant reduction in Research and Development (R&D) expenses, which were down to just $3.3 million for the second quarter of 2025, compared to $5.2 million in the same period in 2024. That's a 37% drop in R&D spend year-over-year for Q2, reflecting effective cost management while maintaining clinical momentum.

The acquisition of VIS-101 (formerly AM712/ASKG712) for ophthalmic therapeutics, completed by a newly formed subsidiary Visara, Inc., is a perfect example of the new strategy. They are acquiring clinical-stage assets with a well-defined proof-of-concept pathway, aiming to reach POC within two to three years. This is a much faster, more capital-efficient path to value creation than traditional, long-cycle discovery. The net loss for Q2 2025 was $(5.5) million, a manageable burn rate given the cash on hand, showing the financial discipline driving the new platform.

Core Values: Innovation, Execution, Patient Focus

While the formal list of core values isn't always front-and-center, the company's actions in 2025 clearly map to a few key principles. Innovation is embodied by the bispecific antibody technology, like givastomig, which is a potential best-in-class therapy.

Execution is demonstrated by completing enrollment for the givastomig Phase 1b expansion cohort ahead of schedule. This operational discipline is crucial for a clinical-stage biotech. Finally, Patient Focus is the north star, with the mission explicitly about accelerating access to transformative medicines for patients worldwide. The entire strategic shift is designed to get novel therapies to the market faster and more efficiently. That's the real measure of their values.

I-Mab (IMAB) Core Values

You're looking past the ticker-I-Mab (IMAB), now NovaBridge Biosciences-and right into the DNA of the company, which is smart. The mission is clear: 'Bringing Transformational Medicines to Patients Through Innovation.' The true measure of that mission, especially for a biotech navigating a strategic pivot, lies in its core values: Innovation, Integrity, and Resilience. These aren't just words; they map directly to their clinical execution and financial strategy in 2025.

The company's recent strategic transformation, including the rebrand to NovaBridge Biosciences effective October 30, 2025, is a direct reflection of these values in action. It's a move to a global biotech platform model, which requires a defintely strong foundation in these principles to succeed.

Innovation

Innovation is the engine of any biotech, and for NovaBridge Biosciences, it's about identifying and accelerating breakthrough assets. This value is best represented by the intense focus on their lead immuno-oncology program, givastomig (a bispecific antibody targeting CLDN18.2 and 4-1BB). This is a precision approach to cancer treatment, the kind of cutting-edge science that actually changes patient outcomes.

The commitment to innovation is measurable in clinical results. In the second quarter of 2025, Phase 1b data for givastomig in combination with immunochemotherapy for first-line gastric cancers showed an impressive 83% objective response rate (ORR). That's a huge signal in a tough-to-treat cancer. Plus, they're not standing still; the company recently expanded its innovative pipeline by acquiring VIS-101, a novel bifunctional biologic for ophthalmic disorders, through its new subsidiary, Visara.

• Accelerate breakthrough assets.
• Prioritize high-potential, differentiated biologics.
• Translate science into life-saving therapies.

Resilience

In the high-risk, high-reward world of drug development, resilience is what keeps the lights on and the trials moving. For a clinical-stage company, this translates directly to financial prudence and strategic agility. You can see this in their disciplined cost management throughout 2025.

The company reduced administrative expenses to $3.8 million in Q2 2025, marking a 68% year-over-year reduction. That's not just belt-tightening; that's a strategic realignment to maximize the cash runway. Here's the quick math: following an August 2025 offering that raised $61.2 million, the pro-forma cash balance stood at approximately $226.8 million as of June 30, 2025, which is projected to fund operations through the fourth quarter of 2028. That three-plus-year runway is a testament to financial resilience, allowing them to focus on clinical execution like the planned global randomized Phase 2 study for givastomig in Q1 2026.

Integrity

Integrity, in this context, is the commitment to ethical governance, transparent operations, and a patient-first approach. It's the bedrock for attracting capital and talent. The company's commitment to high standards is externally validated by an A Rating from MSCI ESG (Environmental, Social, and Governance) received in February 2023.

The strategic move to pursue a dual listing on NASDAQ and the Hong Kong Stock Exchange (HKEX) is also an act of financial integrity; it's about broadening the investor base and enhancing trading liquidity, increasing transparency for global stakeholders. Furthermore, the company's internal focus on People, a key pillar of their ESG commitment, demonstrates integrity by aiming to foster a diverse and inclusive culture. This is the kind of operational integrity that supports long-term value creation. For a deeper dive into the company's operational history and financial model, you can check out I-Mab (IMAB): History, Ownership, Mission, How It Works & Makes Money.